Details of the Drug

General Information of Drug (ID: DM0C9IL)

Drug Name

Ranolazine

Synonyms

RANOLAZINE; 95635-55-5; Ranexa; N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-3-(2-methoxyphenoxy)propyl)piperazin-1-yl)acetamide; CVT-303; (-)-Ranolazine; Ranolazine (Ranexa); Ranolazine 2HCl; RS-43285-003; 142387-99-3; N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide; CHEBI:87690; N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide; C24H33N3O4; NCGC00015897-02; DSSTox_RID_80743; DSSTox_CID_25196; DSSTox_GSID_45196; Ran4; CVT 303; Latixa; RAN D; Latixa; Ranolazine dihydrochloride; KEG-1295; RS-43285; Ranexa (TN); Ranexa, Ranolazine; Ranolazine (USAN/INN); Ranolazine extended-release; Ranolazine/Dronedarone Fixed-Dose Combination

Indication

Disease Entry	ICD 11	Status	REF
Acute coronary syndrome	BA41	Approved	[1]
Angina pectoris	BA40	Approved	[1]
Chronic/stable angina	BA40.1	Approved	[2]
Diarrhea-predominant irritable bowel syndrome	DD91.01	Approved	[1]
Paroxysmal atrial fibrillation	BC81.30	Phase 2	[3]
------------------------------------------------------------------------------------

Therapeutic Class

Analgesics

Affected Organisms

Humans and other mammals

ATC Code

C01EB18: Ranolazine

C01EB: Other cardiac preparations

C01E: OTHER CARDIAC PREPARATIONS

C01: CARDIAC THERAPY

C: CARDIOVASCULAR SYSTEM

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

427.5

Logarithm of the Partition Coefficient (xlogp)

2.7

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [4]
Bioavailability: The bioavailability of drug is 64% [5]
Clearance: The drug present in the plasma can be removed from the body at the rate of 9.5 mL/min/kg [6]
Elimination: An estimated 5% of an ingested dose is excreted as unchanged drug [7]
Half-life: The concentration or amount of drug in body reduced by one-half in 7 hours [8]
Metabolism: The drug is metabolized via the liver [9]
Unbound Fraction: The unbound fraction of drug in plasma is 0.38% [6]
Vd: The volume of distribution (Vd) of drug is 53.2 L [10]

Chemical Identifiers

Formula: C24H33N3O4
IUPAC Name: N-(2,6-dimethylphenyl)-2-[4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl]acetamide
Canonical SMILES: CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O
InChI: InChI=1S/C24H33N3O4/c1-18-7-6-8-19(2)24(18)25-23(29)16-27-13-11-26(12-14-27)15-20(28)17-31-22-10-5-4-9-21(22)30-3/h4-10,20,28H,11-17H2,1-3H3,(H,25,29)
InChIKey: XKLMZUWKNUAPSZ-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 56959
ChEBI ID: CHEBI:87690
CAS Number: 95635-55-5
UNII: A6IEZ5M406
DrugBank ID: DB00243
TTD ID: D03HYQ
VARIDT ID: DR00246
INTEDE ID: DR1394
ACDINA ID: D00584

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Plasminogen (PLG)	TTP86E2	PLMN_HUMAN	Modulator	[11]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[12]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[13]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Acute coronary syndrome

ICD Disease Classification

BA41

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Plasminogen (PLG)	DTT	PLG	8.61E-01	-0.01	-0.09
P-glycoprotein 1 (ABCB1)	DTP	P-GP	9.39E-02	1.07E-01	2.80E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	7.30E-01	-1.91E-02	-1.41E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.04E-02	6.29E-02	3.54E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Ranolazine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Bepridil.	Angina pectoris [BA40]	[14]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Dronedarone.	Angina pectoris [BA40]	[14]
Nifedipine	DMSVOZT	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Nifedipine.	Angina pectoris [BA40]	[15]
-----------

Coadministration of a Drug Treating the Disease Different from Ranolazine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylergonovine	DMBEX4O	Moderate	Decreased metabolism of Ranolazine caused by Methylergonovine mediated inhibition of CYP450 enzyme.	Abortion [JA00]	[16]
Sarecycline	DMLZNIQ	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Sarecycline .	Acne vulgaris [ED80]	[15]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Ivosidenib.	Acute myeloid leukaemia [2A60]	[17]
Midostaurin	DMI6E0R	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Midostaurin.	Acute myeloid leukaemia [2A60]	[18]
Idarubicin	DMM0XGL	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Idarubicin.	Acute myeloid leukaemia [2A60]	[19]
Daunorubicin	DMQUSBT	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Daunorubicin.	Acute myeloid leukaemia [2A60]	[19]
Arn-509	DMT81LZ	Major	Increased metabolism of Ranolazine caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[15]
Gilteritinib	DMTI0ZO	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Gilteritinib.	Acute myeloid leukaemia [2A60]	[20]
Oliceridine	DM6MDCF	Major	Decreased metabolism of Ranolazine caused by Oliceridine mediated inhibition of CYP450 enzyme.	Acute pain [MG31]	[21]
Mitotane	DMU1GX0	Major	Increased metabolism of Ranolazine caused by Mitotane mediated induction of CYP450 enzyme.	Adrenal cancer [2D11]	[15]
Terfenadine	DM4KLPT	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Terfenadine.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[18]
Tripelennamine	DMZBU15	Minor	Decreased metabolism of Ranolazine caused by Tripelennamine mediated inhibition of CYP450 enzyme.	Allergic/hypersensitivity disorder [4A80-4A8Z]	[15]
Tacrine	DM51FY6	Moderate	Increased risk of ventricular arrhythmias by the combination of Ranolazine and Tacrine.	Alzheimer disease [8A20]	[14]
Galantamine	DMEO794	Moderate	Decreased metabolism of Ranolazine caused by Galantamine mediated inhibition of CYP450 enzyme.	Alzheimer disease [8A20]	[15]
Rivastigmine	DMG629M	Moderate	Increased risk of ventricular arrhythmias by the combination of Ranolazine and Rivastigmine.	Alzheimer disease [8A20]	[14]
Donepezil	DMIYG7Z	Minor	Decreased metabolism of Ranolazine caused by Donepezil mediated inhibition of CYP450 enzyme.	Alzheimer disease [8A20]	[22]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Ranolazine and Metronidazole.	Amoebiasis [1A36]	[23]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[24]
Methylphenobarbital	DMDSWAG	Major	Increased metabolism of Ranolazine caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[25]
Hydroxyzine	DMF8Y74	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[18]
Clobazam - Lundbeck	DMW1OQ0	Minor	Decreased metabolism of Ranolazine caused by Clobazam - Lundbeck mediated inhibition of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[15]
Promazine	DMZAL7W	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Promazine.	Appearance/behaviour symptom [MB23]	[18]
Voriconazole	DMAOL2S	Major	Decreased metabolism of Ranolazine caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[23]
Posaconazole	DMUL5EW	Major	Decreased metabolism of Ranolazine caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[23]
Levalbuterol	DM5YBO1	Moderate	Increased risk of ventricular arrhythmias by the combination of Ranolazine and Levalbuterol.	Asthma [CA23]	[26]
Terbutaline	DMD4381	Moderate	Increased risk of ventricular arrhythmias by the combination of Ranolazine and Terbutaline.	Asthma [CA23]	[27]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Ranolazine and Pirbuterol.	Asthma [CA23]	[27]
Budesonide	DMJIBAW	Moderate	Decreased metabolism of Ranolazine caused by Budesonide mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[28]
Salbutamol	DMN9CWF	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Salbutamol.	Asthma [CA23]	[26]
Formoterol	DMSOURV	Moderate	Increased risk of ventricular arrhythmias by the combination of Ranolazine and Formoterol.	Asthma [CA23]	[27]
Pimecrolimus	DMZLGRB	Minor	Decreased metabolism of Ranolazine caused by Pimecrolimus mediated inhibition of CYP450 enzyme.	Atopic eczema [EA80]	[29]
Atomoxetine	DM5L6HI	Moderate	Decreased metabolism of Ranolazine caused by Atomoxetine mediated inhibition of CYP450 enzyme.	Attention deficit hyperactivity disorder [6A05]	[30]
Lisdexamfetamine	DM6W8V5	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[20]
Desipramine	DMT2FDC	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[18]
Ofloxacin	DM0VQN3	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Ciprofloxacin XR	DM2NLS9	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[18]
Dalfopristin	DM4LTKV	Major	Decreased metabolism of Ranolazine caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[18]
Clarithromycin	DM4M1SG	Major	Decreased metabolism of Ranolazine caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[23]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Ranolazine and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[14]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[31]
Gemifloxacin	DMHT34O	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Norfloxacin	DMIZ6W2	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Levofloxacin	DMS60RB	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Levofloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Lomefloxacin	DMVRH9C	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[18]
Telithromycin	DMZ4P3A	Major	Decreased metabolism of Ranolazine caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[23]
Retigabine	DMGNYIH	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Retigabine.	Behcet disease [4A62]	[18]
Cariprazine	DMJYDVK	Moderate	Decreased metabolism of Ranolazine caused by Cariprazine mediated inhibition of CYP450 enzyme.	Bipolar disorder [6A60]	[20]
Erdafitinib	DMI782S	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[32]
Loperamide	DMOJZQ9	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Loperamide.	Bowel habit change [ME05]	[33]
Eribulin	DM1DX4Q	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Eribulin.	Breast cancer [2C60-2C6Y]	[14]
Talazoparib	DM1KS78	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Talazoparib.	Breast cancer [2C60-2C6Y]	[20]
Lapatinib	DM3BH1Y	Major	Decreased metabolism of Ranolazine caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[15]
LY2835219	DM93VBZ	Moderate	Decreased metabolism of Ranolazine caused by LY2835219 mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[34]
Tucatinib	DMBESUA	Major	Decreased metabolism of Ranolazine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[23]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Ranolazine caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[20]
Alpelisib	DMEXMYK	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Alpelisib.	Breast cancer [2C60-2C6Y]	[15]
Tamoxifen	DMLB0EZ	Major	Decreased metabolism of Ranolazine caused by Tamoxifen mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[35]
Cabazitaxel	DMPAZHC	Moderate	Decreased metabolism of Ranolazine caused by Cabazitaxel mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[36]
Toremifene	DMQYUWG	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Toremifene.	Breast cancer [2C60-2C6Y]	[14]
Bosutinib	DMTI8YE	Moderate	Decreased metabolism of Ranolazine caused by Bosutinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[20]
Grepafloxacin	DMGLX0T	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Grepafloxacin.	Bronchitis [CA20]	[31]
Sotalol	DML60TN	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Sotalol.	Cardiac arrhythmia [BC9Z]	[14]
Atorvastatin	DMF28YC	Major	Decreased metabolism of Ranolazine caused by Atorvastatin mediated inhibition of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[20]
Macitentan	DMP79A1	Moderate	Decreased metabolism of Ranolazine caused by Macitentan mediated inhibition of CYP450 enzyme.	Cardiovascular disease [BA00-BE2Z]	[37]
Secobarbital	DM14RF5	Major	Increased metabolism of Ranolazine caused by Secobarbital mediated induction of CYP450 enzyme.	Chronic insomnia [7A00]	[15]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Ranolazine and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[27]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Ranolazine and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[26]
Salmeterol	DMIEU69	Moderate	Increased risk of ventricular arrhythmias by the combination of Ranolazine and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[27]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Ranolazine and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[27]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Ranolazine and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[27]
Phenylbutazone	DMAYL0T	Major	Increased metabolism of Ranolazine caused by Phenylbutazone mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[15]
Fidaxomicin	DMFP6MV	Minor	Decreased clearance of Ranolazine due to the transporter inhibition by Fidaxomicin.	Clostridium difficile enterocolitis [1A04]	[23]
Irinotecan	DMP6SC2	Moderate	Decreased metabolism of Ranolazine caused by Irinotecan mediated inhibition of CYP450 enzyme.	Colorectal cancer [2B91]	[14]
Oxaliplatin	DMQNWRD	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Oxaliplatin.	Colorectal cancer [2B91]	[18]
Intedanib	DMSTA36	Moderate	Decreased metabolism of Ranolazine caused by Intedanib mediated inhibition of CYP450 enzyme.	Colorectal cancer [2B91]	[38]
Isoproterenol	DMK7MEY	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Isoproterenol.	Conduction disorder [BC63]	[26]
Ulipristal	DMBNI20	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Ulipristal.	Contraceptive management [QA21]	[15]
Halothane	DM80OZ5	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Halothane.	Corneal disease [9A76-9A78]	[18]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Propofol.	Corneal disease [9A76-9A78]	[39]
Ropivacaine	DMSPJG2	Minor	Decreased metabolism of Ranolazine caused by Ropivacaine mediated inhibition of CYP450 enzyme.	Corneal disease [9A76-9A78]	[40]
Alfentanil	DMVO0UB	Moderate	Decreased metabolism of Ranolazine caused by Alfentanil mediated inhibition of CYP450 enzyme.	Corneal disease [9A76-9A78]	[41]
Probucol	DMVZQ2M	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Probucol.	Coronary atherosclerosis [BA80]	[18]
Methadone	DMTW6IU	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Methadone.	Cough [MD12]	[14]
Dextromethorphan	DMUDJZM	Moderate	Decreased metabolism of Ranolazine caused by Dextromethorphan mediated inhibition of CYP450 enzyme.	Cough [MD12]	[23]
Clofazimine	DMEBOFW	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Clofazimine.	Crohn disease [DD70]	[42]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Pasireotide.	Cushing syndrome [5A70]	[14]
Aminoglutethimide	DMWFHMZ	Major	Increased metabolism of Ranolazine caused by Aminoglutethimide mediated induction of CYP450 enzyme.	Cushing syndrome [5A70]	[15]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Ranolazine caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[25]
Ivacaftor	DMZC1HS	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Ivacaftor.	Cystic fibrosis [CA25]	[15]
MK-8228	DMOB58Q	Major	Decreased metabolism of Ranolazine caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[15]
Rivaroxaban	DMQMBZ1	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Rivaroxaban.	Deep vein thrombosis [BD71]	[43]
Aprepitant	DM053KT	Major	Decreased metabolism of Ranolazine caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[15]
Sertraline	DM0FB1J	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Sertraline.	Depression [6A70-6A7Z]	[18]
Trimipramine	DM1SC8M	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Trimipramine.	Depression [6A70-6A7Z]	[18]
Imipramine	DM2NUH3	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Imipramine.	Depression [6A70-6A7Z]	[18]
Fluoxetine	DM3PD2C	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Fluoxetine.	Depression [6A70-6A7Z]	[18]
Nortriptyline	DM4KDYJ	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Nortriptyline.	Depression [6A70-6A7Z]	[18]
Nefazodone	DM4ZS8M	Major	Decreased metabolism of Ranolazine caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[23]
Paroxetine	DM5PVQE	Moderate	Decreased metabolism of Ranolazine caused by Paroxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[15]
Duloxetine	DM9BI7M	Moderate	Decreased metabolism of Ranolazine caused by Duloxetine mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[44]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Escitalopram.	Depression [6A70-6A7Z]	[14]
OPC-34712	DMHG57U	Major	Decreased metabolism of Ranolazine caused by OPC-34712 mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[45]
Clomipramine	DMINRKW	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Clomipramine.	Depression [6A70-6A7Z]	[18]
Trazodone	DMK1GBJ	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Trazodone.	Depression [6A70-6A7Z]	[46]
Amitriptyline	DMK7F9S	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Amitriptyline.	Depression [6A70-6A7Z]	[18]
Amoxapine	DMKITQE	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Amoxapine.	Depression [6A70-6A7Z]	[18]
Mirtazapine	DML53ZJ	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Mirtazapine.	Depression [6A70-6A7Z]	[47]
Protriptyline	DMNHTZI	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Protriptyline.	Depression [6A70-6A7Z]	[18]
Doxepin	DMPI98T	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Doxepin.	Depression [6A70-6A7Z]	[18]
Maprotiline	DMPWB7T	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Maprotiline.	Depression [6A70-6A7Z]	[18]
Venlafaxine	DMR6QH0	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Venlafaxine.	Depression [6A70-6A7Z]	[18]
Griseofulvin	DMK54YG	Major	Increased metabolism of Ranolazine caused by Griseofulvin mediated induction of CYP450 enzyme.	Dermatophytosis [1F28]	[15]
Polatuzumab vedotin	DMF6Y0L	Moderate	Decreased metabolism of Ranolazine caused by Polatuzumab vedotin mediated inhibition of CYP450 enzyme.	Diffuse large B-cell lymphoma [2A81]	[48]
Tetrabenazine	DMYWQ0O	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[18]
Fenfluramine	DM0762O	Moderate	Decreased metabolism of Ranolazine caused by Fenfluramine mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Primidone	DM0WX6I	Major	Increased metabolism of Ranolazine caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Felbamate	DM1V5ZS	Major	Increased metabolism of Ranolazine caused by Felbamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Oxcarbazepine	DM5PU6O	Major	Increased metabolism of Ranolazine caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Cenobamate	DM8KLU9	Major	Increased metabolism of Ranolazine caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Ranolazine caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[20]
Fosphenytoin	DMOX3LB	Major	Increased metabolism of Ranolazine caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Phenobarbital	DMXZOCG	Major	Increased metabolism of Ranolazine caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[15]
Diphenhydramine	DMKQTBA	Moderate	Decreased metabolism of Ranolazine caused by Diphenhydramine mediated inhibition of CYP450 enzyme.	Episodic vestibular syndrome [AB31]	[15]
Timolol	DM3NXRU	Moderate	Decreased metabolism of Ranolazine caused by Timolol mediated inhibition of CYP450 enzyme.	Essential hypertension [BA00]	[15]
Nicardipine	DMCDYW7	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Nicardipine.	Essential hypertension [BA00]	[15]
Bay 80-6946	DMLOS5R	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Bay 80-6946.	Follicular lymphoma [2A80]	[49]
Tazemetostat	DMWP1BH	Major	Increased metabolism of Ranolazine caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[15]
Solifenacin	DMG592Q	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Solifenacin.	Functional bladder disorder [GC50]	[18]
Mirabegron	DMS1GYT	Minor	Decreased metabolism of Ranolazine caused by Mirabegron mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[15]
Tolterodine	DMSHPW8	Minor	Decreased metabolism of Ranolazine caused by Tolterodine mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[50]
Darifenacin	DMWXLYZ	Moderate	Decreased metabolism of Ranolazine caused by Darifenacin mediated inhibition of CYP450 enzyme.	Functional bladder disorder [GC50]	[51]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Ranolazine caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[23]
Pentamidine	DMHZJCG	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Pentamidine.	Fungal infection [1F29-1F2F]	[18]
Terbinafine	DMI6HUW	Minor	Decreased metabolism of Ranolazine caused by Terbinafine mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[15]
Clotrimazole	DMMFCIH	Major	Decreased metabolism of Ranolazine caused by Clotrimazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[15]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Ranolazine caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[52]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Ranolazine caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[23]
Cimetidine	DMH61ZB	Minor	Decreased metabolism of Ranolazine caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[15]
Cisapride	DMY7PED	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Cisapride.	Gastro-oesophageal reflux disease [DA22]	[14]
Ripretinib	DM958QB	Moderate	Decreased metabolism of Ranolazine caused by Ripretinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[23]
Sunitinib	DMCBJSR	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[18]
Avapritinib	DMK2GZX	Moderate	Decreased metabolism of Ranolazine caused by Avapritinib mediated inhibition of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[20]
Sulfinpyrazone	DMEV954	Major	Increased metabolism of Ranolazine caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[15]
Ergotamine	DMKR3C5	Moderate	Decreased metabolism of Ranolazine caused by Ergotamine mediated inhibition of CYP450 enzyme.	Headache [8A80-8A84]	[53]
Spironolactone	DM2AQ5N	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Spironolactone.	Heart failure [BD10-BD1Z]	[15]
Carvedilol	DMHTEAO	Moderate	Decreased metabolism of Ranolazine caused by Carvedilol mediated inhibition of CYP450 enzyme.	Heart failure [BD10-BD1Z]	[15]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Ranolazine caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[23]
Telaprevir	DMMRV29	Major	Decreased metabolism of Ranolazine caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[23]
GS-5885	DMSL3DX	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by GS-5885.	Hepatitis virus infection [1E50-1E51]	[15]
Rifampin	DMA8J1G	Major	Increased metabolism of Ranolazine caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[25]
Rifapentine	DMCHV4I	Major	Increased metabolism of Ranolazine caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[15]
Brentuximab vedotin	DMWLC57	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[54]
MK-1439	DM215WE	Minor	Decreased metabolism of Ranolazine caused by MK-1439 mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[55]
Delavirdine	DM3NF5G	Major	Decreased metabolism of Ranolazine caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Ranolazine caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Fostemsavir	DM50ILT	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Ranolazine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Efavirenz	DMC0GSJ	Major	Increased metabolism of Ranolazine caused by Efavirenz mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Saquinavir	DMG814N	Major	Decreased metabolism of Ranolazine caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Etravirine	DMGV8QU	Major	Increased metabolism of Ranolazine caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[15]
Rilpivirine	DMJ0QOW	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[18]
Amprenavir	DMLMXE0	Major	Decreased metabolism of Ranolazine caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Darunavir	DMN3GCH	Major	Decreased metabolism of Ranolazine caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Atazanavir	DMSYRBX	Major	Decreased metabolism of Ranolazine caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Maraviroc	DMTL94F	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Maraviroc.	Human immunodeficiency virus disease [1C60-1C62]	[56]
Simvastatin	DM30SGU	Major	Decreased metabolism of Ranolazine caused by Simvastatin mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[20]
BMS-201038	DMQTAGO	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by BMS-201038.	Hyper-lipoproteinaemia [5C80]	[57]
Cerivastatin	DMXCM7H	Moderate	Decreased metabolism of Ranolazine caused by Cerivastatin mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[58]
Cinacalcet	DMCX0K3	Minor	Decreased metabolism of Ranolazine caused by Cinacalcet mediated inhibition of CYP450 enzyme.	Hyper-parathyroidism [5A51]	[15]
Aliskiren	DM1BV7W	Moderate	Decreased metabolism of Ranolazine caused by Aliskiren mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[14]
Nebivolol	DM7F1PA	Moderate	Decreased metabolism of Ranolazine caused by Nebivolol mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[15]
Verapamil	DMA7PEW	Major	Decreased metabolism of Ranolazine caused by Verapamil mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[15]
Diltiazem	DMAI7ZV	Major	Decreased metabolism of Ranolazine caused by Diltiazem mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[15]
Pindolol	DMD2NV7	Moderate	Decreased metabolism of Ranolazine caused by Pindolol mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[15]
Metoprolol	DMOJ0V6	Moderate	Decreased metabolism of Ranolazine caused by Metoprolol mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[15]
Felodipine	DMOSW35	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Felodipine.	Hypertension [BA00-BA04]	[15]
Conivaptan	DM1V329	Major	Decreased metabolism of Ranolazine caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[15]
Tolvaptan	DMIWFRL	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[59]
Pirfenidone	DM6VZFQ	Moderate	Decreased metabolism of Ranolazine caused by Pirfenidone mediated inhibition of CYP450 enzyme.	Idiopathic interstitial pneumonitis [CB03]	[20]
Givosiran	DM5PFIJ	Minor	Decreased metabolism of Ranolazine caused by Givosiran mediated inhibition of CYP450 enzyme.	Inborn porphyrin/heme metabolism error [5C58]	[15]
Berotralstat	DMWA2DZ	Major	Decreased clearance of Ranolazine due to the transporter inhibition by Berotralstat.	Innate/adaptive immunodeficiency [4A00]	[60]
Suvorexant	DM0E6S3	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Suvorexant.	Insomnia [7A00-7A0Z]	[15]
Amobarbital	DM0GQ8N	Major	Increased metabolism of Ranolazine caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[15]
Pentobarbital	DMFNH7L	Major	Increased metabolism of Ranolazine caused by Pentobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[15]
ITI-007	DMUQ1DO	Moderate	Decreased metabolism of Ranolazine caused by ITI-007 mediated inhibition of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[61]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of ventricular arrhythmias by the combination of Ranolazine and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[20]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Ranolazine and Phenolphthalein.	Irritable bowel syndrome [DD91]	[14]
Naloxegol	DML0B41	Minor	Decreased metabolism of Ranolazine caused by Naloxegol mediated inhibition of CYP450 enzyme.	Large intestine motility disorder [DB32]	[62]
Pemigatinib	DM819JF	Moderate	Decreased metabolism of Ranolazine caused by Pemigatinib mediated inhibition of CYP450 enzyme.	Liver cancer [2C12]	[20]
Glycerol phenylbutyrate	DMDGRQO	Minor	Decreased metabolism of Ranolazine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[15]
Crizotinib	DM4F29C	Major	Decreased metabolism of Ranolazine caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[15]
Brigatinib	DM7W94S	Moderate	Decreased metabolism of Ranolazine caused by Brigatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[23]
Lurbinectedin	DMEFRTZ	Moderate	Decreased metabolism of Ranolazine caused by Lurbinectedin mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[63]
PF-06463922	DMKM7EW	Major	Increased metabolism of Ranolazine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[15]
Dacomitinib	DMOH8VY	Minor	Decreased metabolism of Ranolazine caused by Dacomitinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[15]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Osimertinib.	Lung cancer [2C25]	[64]
Pralsetinib	DMWU0I2	Moderate	Decreased metabolism of Ranolazine caused by Pralsetinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[65]
Capmatinib	DMYCXKL	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Capmatinib.	Lung cancer [2C25]	[15]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Selpercatinib.	Lung cancer [2C25]	[20]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Lumefantrine.	Malaria [1F40-1F45]	[23]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Halofantrine.	Malaria [1F40-1F45]	[66]
Chloroquine	DMSI5CB	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Chloroquine.	Malaria [1F40-1F45]	[67]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Hydroxychloroquine.	Malaria [1F40-1F45]	[67]
Quinine	DMSWYF5	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Quinine.	Malaria [1F40-1F45]	[18]
Primaquine	DMWQ16I	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Primaquine.	Malaria [1F40-1F45]	[18]
Mefloquine	DMWT905	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Mefloquine.	Malaria [1F40-1F45]	[18]
Inotuzumab ozogamicin	DMAC130	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[18]
Idelalisib	DM602WT	Major	Decreased metabolism of Ranolazine caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[23]
GDC-0199	DMH0QKA	Major	Decreased clearance of Ranolazine due to the transporter inhibition by GDC-0199.	Mature B-cell leukaemia [2A82]	[23]
IPI-145	DMWA24P	Major	Decreased metabolism of Ranolazine caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[15]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Ranolazine and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[68]
Acalabrutinib	DM7GCVW	Moderate	Decreased metabolism of Ranolazine caused by Acalabrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[69]
Ibrutinib	DMHZCPO	Moderate	Decreased metabolism of Ranolazine caused by Ibrutinib mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[70]
Vincristine	DMINOX3	Moderate	Decreased metabolism of Ranolazine caused by Vincristine mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[71]
Ponatinib	DMYGJQO	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Ponatinib.	Mature B-cell lymphoma [2A85]	[15]
Arry-162	DM1P6FR	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Arry-162.	Melanoma [2C30]	[23]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Vemurafenib.	Melanoma [2C30]	[14]
Selumetinib	DMC7W6R	Moderate	Decreased metabolism of Ranolazine caused by Selumetinib mediated inhibition of CYP450 enzyme.	Melanoma [2C30]	[72]
LGX818	DMNQXV8	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and LGX818.	Melanoma [2C30]	[73]
Nitisinone	DMVS9WQ	Moderate	Decreased metabolism of Ranolazine caused by Nitisinone mediated inhibition of CYP450 enzyme.	Metabolism inborn error [5C50]	[14]
Methysergide	DM1EF73	Moderate	Decreased metabolism of Ranolazine caused by Methysergide mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[16]
Dihydroergotamine	DM5IKUF	Moderate	Decreased metabolism of Ranolazine caused by Dihydroergotamine mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[53]
Ubrogepant	DM749I3	Moderate	Decreased metabolism of Ranolazine caused by Ubrogepant mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[74]
Propranolol	DM79NTF	Moderate	Decreased metabolism of Ranolazine caused by Propranolol mediated inhibition of CYP450 enzyme.	Migraine [8A80]	[15]
Rimegepant	DMHOAUG	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Rimegepant.	Migraine [8A80]	[75]
Lasmiditan	DMXLVDT	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Lasmiditan.	Migraine [8A80]	[76]
Midazolam	DMXOELT	Moderate	Decreased metabolism of Ranolazine caused by Midazolam mediated inhibition of CYP450 enzyme.	Mood/affect symptom [MB24]	[71]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Panobinostat.	Multiple myeloma [2A83]	[77]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Ranolazine and Thalidomide.	Multiple myeloma [2A83]	[23]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Ranolazine and Siponimod.	Multiple sclerosis [8A40]	[23]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Ranolazine and Fingolimod.	Multiple sclerosis [8A40]	[14]
Ozanimod	DMT6AM2	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Ozanimod.	Multiple sclerosis [8A40]	[18]
Rifabutin	DM1YBHK	Major	Increased metabolism of Ranolazine caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[15]
Bexarotene	DMOBIKY	Major	Increased metabolism of Ranolazine caused by Bexarotene mediated induction of CYP450 enzyme.	Mycosis fungoides [2B01]	[15]
Fedratinib	DM4ZBK6	Major	Decreased metabolism of Ranolazine caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[15]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Nilotinib.	Myeloproliferative neoplasm [2A20]	[14]
Ruxolitinib	DM7Q98D	Minor	Decreased metabolism of Ranolazine caused by Ruxolitinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[20]
Imatinib	DM7RJXL	Major	Decreased metabolism of Ranolazine caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[15]
Dasatinib	DMJV2EK	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Dasatinib.	Myeloproliferative neoplasm [2A20]	[18]
Modafinil	DMYILBE	Major	Increased metabolism of Ranolazine caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[15]
Droperidol	DM0DXA8	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Droperidol.	Nausea/vomiting [MD90]	[14]
Prochlorperazine	DM53SRA	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Prochlorperazine.	Nausea/vomiting [MD90]	[18]
Promethazine	DM6I5GR	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Promethazine.	Nausea/vomiting [MD90]	[18]
Rolapitant	DM8XP26	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Rolapitant.	Nausea/vomiting [MD90]	[78]
Cyclizine	DM9G7BS	Minor	Decreased metabolism of Ranolazine caused by Cyclizine mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[15]
Palonosetron	DMBHMOX	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Palonosetron.	Nausea/vomiting [MD90]	[18]
Netupitant	DMEKAYI	Major	Decreased metabolism of Ranolazine caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[18]
Granisetron	DMIUW25	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Granisetron.	Nausea/vomiting [MD90]	[18]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Dolasetron.	Nausea/vomiting [MD90]	[14]
Ondansetron	DMOTQ1I	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Ondansetron.	Nausea/vomiting [MD90]	[18]
Bupropion	DM5PCS7	Minor	Decreased metabolism of Ranolazine caused by Bupropion mediated inhibition of CYP450 enzyme.	Nicotine use disorder [6C4A]	[15]
Entrectinib	DMMPTLH	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Entrectinib.	Non-small cell lung cancer [2C25]	[23]
Lorcaserin	DMG6OYJ	Minor	Decreased metabolism of Ranolazine caused by Lorcaserin mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[15]
Dexfenfluramine	DMJ7YDS	Moderate	Decreased metabolism of Ranolazine caused by Dexfenfluramine mediated inhibition of CYP450 enzyme.	Obesity [5B80-5B81]	[15]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Levomethadyl Acetate.	Opioid use disorder [6C43]	[20]
Lofexidine	DM1WXA6	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Lofexidine.	Opioid use disorder [6C43]	[14]
S-297995	DM26IH8	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by S-297995.	Opioid use disorder [6C43]	[20]
Olaparib	DM8QB1D	Moderate	Decreased metabolism of Ranolazine caused by Olaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[79]
Rucaparib	DM9PVX8	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Rucaparib.	Ovarian cancer [2C73]	[18]
Dextropropoxyphene	DM23HCX	Moderate	Decreased metabolism of Ranolazine caused by Dextropropoxyphene mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[15]
Codeine	DMJX6ZG	Moderate	Decreased metabolism of Ranolazine caused by Codeine mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[80]
Methamphetamine	DMPM4SK	Moderate	Decreased metabolism of Ranolazine caused by Methamphetamine mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[15]
Buprenorphine	DMPRI8G	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Buprenorphine.	Pain [MG30-MG3Z]	[14]
Oxycodone	DMXLKHV	Major	Decreased metabolism of Ranolazine caused by Oxycodone mediated inhibition of CYP450 enzyme.	Pain [MG30-MG3Z]	[23]
Triclabendazole	DMPWGBR	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Triclabendazole.	Parasitic worm infestation [1F90]	[18]
Istradefylline	DM20VSK	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Istradefylline.	Parkinsonism [8A00]	[15]
Pimavanserin	DMR7IVC	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Pimavanserin.	Parkinsonism [8A00]	[81]
Apomorphine	DMX38HQ	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Apomorphine.	Parkinsonism [8A00]	[18]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Famotidine.	Peptic ulcer [DA61]	[23]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[82]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Lefamulin.	Pneumonia [CA40]	[83]
Ergonovine	DM0VEC1	Moderate	Decreased metabolism of Ranolazine caused by Ergonovine mediated inhibition of CYP450 enzyme.	Postpartum haemorrhage [JA43]	[16]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Ranolazine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[23]
Ritodrine	DM4V6RL	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Ritodrine.	Preterm labour/delivery [JB00]	[27]
Progesterone	DMUY35B	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Progesterone.	Preterm labour/delivery [JB00]	[15]
Degarelix	DM3O8QY	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Degarelix.	Prostate cancer [2C82]	[20]
ABIRATERONE	DM8V75C	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and ABIRATERONE.	Prostate cancer [2C82]	[20]
Nilutamide	DMFN07X	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Nilutamide.	Prostate cancer [2C82]	[20]
Enzalutamide	DMGL19D	Major	Increased metabolism of Ranolazine caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[15]
Flutamide	DMK0O7U	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Flutamide.	Prostate cancer [2C82]	[20]
Relugolix	DMK7IWL	Major	Decreased clearance of Ranolazine due to the transporter inhibition by Relugolix.	Prostate cancer [2C82]	[84]
Darolutamide	DMV7YFT	Minor	Decreased metabolism of Ranolazine caused by Darolutamide mediated inhibition of CYP450 enzyme.	Prostate cancer [2C82]	[85]
Tamsulosin	DM5QF9V	Moderate	Decreased metabolism of Ranolazine caused by Tamsulosin mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[86]
Silodosin	DMJSBT6	Moderate	Decreased metabolism of Ranolazine caused by Silodosin mediated inhibition of CYP450 enzyme.	Prostate hyperplasia [GA90]	[87]
Alfuzosin	DMZVMKF	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Alfuzosin.	Prostate hyperplasia [GA90]	[18]
Levomepromazine	DMIKFEL	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Levomepromazine.	Psychotic disorder [6A20-6A25]	[18]
Fluphenazine	DMIT8LX	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Fluphenazine.	Psychotic disorder [6A20-6A25]	[18]
Triflupromazine	DMKFQJP	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Triflupromazine.	Psychotic disorder [6A20-6A25]	[18]
Bosentan	DMIOGBU	Major	Increased metabolism of Ranolazine caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[15]
Riociguat	DMXBLMP	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Riociguat.	Pulmonary hypertension [BB01]	[23]
Everolimus	DM8X2EH	Moderate	Decreased metabolism of Ranolazine caused by Everolimus mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[88]
Axitinib	DMGVH6N	Moderate	Decreased metabolism of Ranolazine caused by Axitinib mediated inhibition of CYP450 enzyme.	Renal cell carcinoma [2C90]	[20]
Sorafenib	DMS8IFC	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Sorafenib.	Renal cell carcinoma [2C90]	[14]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[89]
Celecoxib	DM6LOQU	Minor	Decreased metabolism of Ranolazine caused by Celecoxib mediated inhibition of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[15]
Dexamethasone	DMMWZET	Major	Increased metabolism of Ranolazine caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[15]
Nafcillin	DMN9RPO	Major	Increased metabolism of Ranolazine caused by Nafcillin mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[15]
Oxamniquine	DM2QDX1	Moderate	Decreased metabolism of Ranolazine caused by Oxamniquine mediated inhibition of CYP450 enzyme.	Schistosomiasis [1F86]	[15]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Mesoridazine.	Schizophrenia [6A20]	[14]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Thioridazine.	Schizophrenia [6A20]	[14]
Aripiprazole	DM3NUMH	Moderate	Decreased metabolism of Ranolazine caused by Aripiprazole mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[90]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Iloperidone.	Schizophrenia [6A20]	[14]
Paliperidone	DM7NPJS	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Paliperidone.	Schizophrenia [6A20]	[18]
Haloperidol	DM96SE0	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Haloperidol.	Schizophrenia [6A20]	[14]
Perphenazine	DMA4MRX	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Perphenazine.	Schizophrenia [6A20]	[18]
Chlorpromazine	DMBGZI3	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Chlorpromazine.	Schizophrenia [6A20]	[18]
Clozapine	DMFC71L	Moderate	Decreased metabolism of Ranolazine caused by Clozapine mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[15]
Trifluoperazine	DMKBYWI	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Trifluoperazine.	Schizophrenia [6A20]	[18]
Ziprasidone	DMM58JY	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Ziprasidone.	Schizophrenia [6A20]	[14]
Risperidone	DMN6DXL	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Risperidone.	Schizophrenia [6A20]	[18]
Olanzapine	DMPFN6Y	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Olanzapine.	Schizophrenia [6A20]	[23]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Amisulpride.	Schizophrenia [6A20]	[91]
Asenapine	DMSQZE2	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Asenapine.	Schizophrenia [6A20]	[14]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Pimozide.	Schizophrenia [6A20]	[20]
Fentanyl	DM8WAHT	Moderate	Decreased metabolism of Ranolazine caused by Fentanyl mediated inhibition of CYP450 enzyme.	Sensation disturbance [MB40]	[71]
Sufentanil	DMU7YEL	Moderate	Decreased metabolism of Ranolazine caused by Sufentanil mediated inhibition of CYP450 enzyme.	Sensation disturbance [MB40]	[71]
Vardenafil	DMTBGW8	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Vardenafil.	Sexual dysfunction [HA00-HA01]	[18]
Voxelotor	DMCS6M5	Major	Decreased metabolism of Ranolazine caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[15]
LDE225	DMM9F25	Moderate	Decreased metabolism of Ranolazine caused by LDE225 mediated inhibition of CYP450 enzyme.	Skin cancer [2C30-2C37]	[92]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Ranolazine caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[20]
Gefitinib	DM15F0X	Minor	Decreased metabolism of Ranolazine caused by Gefitinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[15]
Cyclophosphamide	DM4O2Z7	Minor	Decreased metabolism of Ranolazine caused by Cyclophosphamide mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[20]
Vinblastine	DM5TVS3	Moderate	Decreased metabolism of Ranolazine caused by Vinblastine mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[71]
Docetaxel	DMDI269	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Docetaxel.	Solid tumour/cancer [2A00-2F9Z]	[93]
Trabectedin	DMG3Y89	Moderate	Decreased metabolism of Ranolazine caused by Trabectedin mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[20]
Armodafinil	DMGB035	Major	Increased metabolism of Ranolazine caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[15]
LEE011	DMMX75K	Major	Increased risk of prolong QT interval by the combination of Ranolazine and LEE011.	Solid tumour/cancer [2A00-2F9Z]	[14]
Epirubicin	DMPDW6T	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Epirubicin.	Solid tumour/cancer [2A00-2F9Z]	[18]
Triptorelin	DMTK4LS	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[20]
Doxorubicin	DMVP5YE	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[18]
Vinorelbine	DMVXFYE	Moderate	Decreased metabolism of Ranolazine caused by Vinorelbine mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[71]
Pitolisant	DM8RFNJ	Moderate	Decreased metabolism of Ranolazine caused by Pitolisant mediated inhibition of CYP450 enzyme.	Somnolence [MG42]	[20]
Telavancin	DM58VQX	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[18]
Ibutilide	DMKXY2R	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Ibutilide.	Supraventricular tachyarrhythmia [BC81]	[14]
Adenosine	DMM2NSK	Moderate	Increased risk of ventricular arrhythmias by the combination of Ranolazine and Adenosine.	Supraventricular tachyarrhythmia [BC81]	[14]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Ranolazine caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[94]
Lusutrombopag	DMH6IKO	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Lusutrombopag.	Thrombocytopenia [3B64]	[95]
Anagrelide	DMSQ8MD	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Anagrelide.	Thrombocytosis [3B63]	[14]
Apixaban	DM89JLN	Moderate	Decreased metabolism of Ranolazine caused by Apixaban mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[20]
Brilinta	DMBR01X	Moderate	Decreased clearance of Ranolazine due to the transporter inhibition by Brilinta.	Thrombosis [DB61-GB90]	[15]
Lenvatinib	DMB1IU4	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Lenvatinib.	Thyroid cancer [2D10]	[18]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Papaverine.	Tonus and reflex abnormality [MB47]	[96]
Sirolimus	DMGW1ID	Moderate	Decreased metabolism of Ranolazine caused by Sirolimus mediated inhibition of CYP450 enzyme.	Transplant rejection [NE84]	[71]
Tacrolimus	DMZ7XNQ	Moderate	Decreased metabolism of Ranolazine caused by Tacrolimus mediated inhibition of CYP450 enzyme.	Transplant rejection [NE84]	[71]
Astemizole	DM2HN6Q	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Astemizole.	Vasomotor/allergic rhinitis [CA08]	[18]
Chlorpheniramine	DM5URA2	Moderate	Decreased metabolism of Ranolazine caused by Chlorpheniramine mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[15]
Clemastine	DMBZWQL	Minor	Decreased metabolism of Ranolazine caused by Clemastine mediated inhibition of CYP450 enzyme.	Vasomotor/allergic rhinitis [CA08]	[15]
Trimeprazine	DMEMV9D	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[18]
Disopyramide	DM5SYZP	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Disopyramide.	Ventricular tachyarrhythmia [BC71]	[14]
Mexiletine	DMCTE9R	Moderate	Decreased metabolism of Ranolazine caused by Mexiletine mediated inhibition of CYP450 enzyme.	Ventricular tachyarrhythmia [BC71]	[15]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Procainamide.	Ventricular tachyarrhythmia [BC71]	[14]
Propafenone	DMPIBJK	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Propafenone.	Ventricular tachyarrhythmia [BC71]	[18]
Flecainide	DMSQDLE	Moderate	Increased risk of prolong QT interval by the combination of Ranolazine and Flecainide.	Ventricular tachyarrhythmia [BC71]	[18]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Ranolazine and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[14]
-----------


⏷ Show the Full List of 354 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Sunset yellow FCF	E00255	17730	Colorant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol	E00666	Not Available	Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 14 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Ranolazine 500 mg tablet	500 mg	12 HR Extended Release Oral Tablet	Oral
Ranolazine 1000 mg tablet	1000 mg	12 HR Extended Release Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Ranolazine FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7291).
3	Clinical pipeline report, company report or official report of Gilead.
4	BDDCS applied to over 900 drugs
5	Singulair (montelukast sodium) US FDA Label 2019
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Rayner-Hartley E, Sedlak T: Ranolazine: A Contemporary Review. J Am Heart Assoc. 2016 Mar 15;5(3):e003196. doi: 10.1161/JAHA.116.003196.
8	Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation. 2006 May 23;113(20):2462-72. doi: 10.1161/CIRCULATIONAHA.105.597500.
9	Battershill PE, Clissold SP: Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion. Drugs. 1989 Nov;38(5):658-702. doi: 10.2165/00003495-198938050-00002.
10	Australian Assessment Report
11	Tranexamic acid in trauma: how should we use it. J Trauma Acute Care Surg. 2013 Jun;74(6):1575-86.
12	Ranolazine-tacrolimus interaction. Ann Pharmacother. 2010 Nov;44(11):1844-9.
13	Ranolazine: a contemporary review. J Am Heart Assoc. 2016 Mar 15;5(3):e003196.
14	Canadian Pharmacists Association.
15	Product Information. Ranexa (ranolazine). Calmoseptine Inc, Huntington Beach, CA.
16	Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6. [PMID: 6236021]
17	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
18	European Medicines Agency "CHMP Assessment Report for Latixa. International nonproprietary name: ranolazine.".
19	Multum Information Services, Inc. Expert Review Panel.
20	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
21	Product Information. Olinvyk (oliceridine). Trevena Inc, Chesterbrook, PA.
22	Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
23	Cerner Multum, Inc. "Australian Product Information.".
24	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
25	Product Information. Diabinese (chlorpropamide). Pfizer US Pharmaceuticals, New York, NY.
26	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
27	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
28	Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
29	Product Information. Elidel (pimecrolimus topical). Novartis Pharmaceuticals, East Hanover, NJ.
30	Belle DJ, Ernest CS, Sauer JM, Smith BP, Thomasson HR, Witcher JW "Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics." J Clin Pharmacol 42 (2002): 1219-27. [PMID: 12412820]
31	Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
32	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
33	Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
34	Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
35	Amchin J, Ereshefsky L, Zarycranski W, Taylor K, Albano D, Klockowski PM "Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe." J Clin Pharmacol 41 (2001): 443-51. [PMID: 11304901]
36	Product Information. Jevtana (cabazitaxel). sanofi-aventis , Bridgewater, NJ.
37	Product Information. Opsumit (macitentan). Actelion Pharmaceuticals US Inc, South San Francisco, CA.
38	Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
39	Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
40	Ekstrom G, Gunnarsson UB "Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes." Drug Metab Dispos 24 (1996): 955-61. [PMID: 8886604]
41	Bartkowski RR, Goldberg ME, Larijani GE, Boerner T "Inhibition of alfentanil metabolism by erythromycin." Clin Pharmacol Ther 46 (1989): 99-102. [PMID: 2501060]
42	Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
43	Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
44	Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
45	Product Information. Rexulti (brexpiprazole). Otsuka American Pharmaceuticals Inc, Rockville, MD.
46	Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]
47	Product Information. Remeron (mirtazapine). Organon, West Orange, NJ.
48	Product Information. Polivy (polatuzumab vedotin). Genentech, South San Francisco, CA.
49	Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
50	Brynne N, Svanstrom C, AbergWistedt A, Hallen B, Bertilsson L "Fluoxetine inhibits the metabolism of tolterodin-pharmacokinetic implications and proposed clinical relevance." Br J Clin Pharmacol 48 (1999): 553-63. [PMID: 10583026]
51	Product Information. Enablex (darifenacin). Novartis Pharmaceuticals, East Hanover, NJ.
52	Product Information. ORAVIG (miconazole). Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.
53	Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3. [PMID: 11728770]
54	Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
55	Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
56	Product Information. Selzentry (maraviroc). Pfizer U.S. Pharmaceuticals Group, New York, NY.
57	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
58	Agbin NE, Brater DC, Hall SD "Interaction of diltiazem with lovastatin and pravastatin." Clin Pharmacol Ther 61 (1997): 201. [PMID: 9797793]
59	Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
60	Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
61	Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
62	Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
63	Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
64	Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
65	Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
66	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
67	Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
68	Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
69	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
70	Product Information. Imbruvica (ibrutinib). Pharmacyclics Inc, Sunnyvale, CA.
71	Pierce DA, Reeves-Daniel AM "Ranolazine-tacrolimus interaction." Ann Pharmacother 44 (2010): 1844-9. [PMID: 20876828]
72	Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
73	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
74	Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
75	Product Information. Nurtec ODT (rimegepant). Biohaven Pharmaceuticals, New Haven, CT.
76	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
77	Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
78	Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
79	Product Information. Lynparza (olaparib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
80	Caraco Y, Sheller J, Wood AJJ "Impact of ethnic origin and quinidine coadministration on codeine's disposition and pharmacodynamic effects." J Pharmacol Exp Ther 290 (1999): 413-22. [PMID: 10381807]
81	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
82	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
83	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
84	Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
85	Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
86	Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206]
87	Product Information. Rapaflo (silodosin). Watson Pharmaceuticals, Corona, CA.
88	Product Information. Afinitor (everolimus). Novartis Pharmaceuticals, East Hanover, NJ.
89	Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
90	Product Information. Abilify (aripiprazole). Bristol-Myers Squibb, Princeton, NJ.
91	Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
92	Product Information. Odomzo (sonidegib). Novartis Pharmaceuticals, East Hanover, NJ.
93	Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
94	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
95	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
96	Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]